Factors Associated With Clinical Outcomes in Patients Hospitalized for Covid-19 in GHT-93 Est

Study Overview
=================
Brief Summary
-----------------
Healthcare centers treated several hundreds of patients with Covid-19 and prospectively gathered information in electronic format between March, 2020 to April, 2020. In the course of Covid-19 treatment, physicians employed several drugs, including hydroxychloroquine, azithromycin, lopinavir/ritonavir, tocilizumab, baricitinib, sarilumab, corticosteroids and systematic antibiotics (list is not exhaustive). This cohort study aims to assess factors associated with clinical outcomes in patients hospitalized for Covid-19, by analyzing associations between treatments and outcomes. All data are collected in electronical records during routine practice.

Detailed Description
-----------------
Healthcare centers treated several hundreds of patients with Covid-19 and prospectively gathered information in electronic format between March, 2020 to April, 2020. In the course of Covid-19 treatment, physicians employed several drugs, including hydroxychloroquine, azithromycin, lopinavir/ritonavir, tocilizumab, baricitinib, sarilumab, corticosteroids and systematic antibiotics (list is not exhaustive). This cohort study aims to assess factors associated with clinical outcomes in patients hospitalized for Covid-19. Risk factors which will be studied include: baseline characteristics such as medical history and drugs with corresponding administration protocols. Main outcomes include all-cause mortality, need for mechanical ventilation, for ICU transfer and all relevant biological syndromes. All data are collected in electronical records during routine practice and additional data may be collected retrospectively.

Official Title
-----------------
Factors Associated With Clinical Outcomes in Patients Hospitalized for Covid-19 in GHT-93 Est

Conditions
-----------------
COVID, SARS-CoV 2

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: hospitalized for Covid-19 severe pneumonia defined as pulse O2 < 96% despite > 6L/min Exclusion Criteria: lack of consent palliative care patients patients in ICU patients transferred from ICU
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients exposed to the study variable<br>Depending on the studied variable (treatment or risk factor) | |
| Patients not exposed to the study variable<br>Depending on the studied variable (treatment or risk factor) | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Composite of death and mechanical ventilation | Composite of death and mechanical ventilation | At 14-days follow-up | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Need for mechanical ventilation | Need for mechanical ventilation | At 14-days follow-up | 
| Death | All-cause mortality | At 14-days follow-up | 
| Acute kidney injury | As defined by AKIN | At 14-days follow-up | 
| Acute respiratory distress syndrome | As defined by Berlin criteria: P/F ratio below 200, with PEEP > +5 cmH20, radiologic findings compatible with ARDS and not explained by heart failure, occurring within 7 days of an acute pulmonary or non-pulmonary aggression. | At 14-days follow-up | 
| Cardiac arrhythmia and conduction disorder | Documented by EKG monitoring | At 14-days follow-up | 
| Composite of death and mechanical ventilation | Composite of death and mechanical ventilation | Up to 60 days after inclusion | 
| 60-days mortality | All cause mortality at 60 days follow-up whenever possible | Up to 60 days after inclusion | 
| 60-days mechanical ventilation | If patient was mechanically ventilated within 60 days of inclusion | Up to 60 days after inclusion | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
SARS-Cov-2, covid-19